Skip to content

Postoperative Pain in the Surgical Treatment of Hemorrhoids: Conventional Hemorrhoidectomy With a Monopolar Electric Scaler VS Bipolar Energy With Caiman® (Aesculap®)

Prospective Randomized Study on Postoperative Pain in the Surgical Treatment of Hemorrhoids Through Conventional Hemorrhoidectomy With a Monopolar Electric Scalpel or Bipolar Energy With Caiman® (Aesculap®)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06535269
Acronym
TAUHEMOR
Enrollment
27
Registered
2024-08-02
Start date
2022-11-02
Completion date
2025-07-31
Last updated
2024-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhoidectomy, Hemorrhoid Pain

Brief summary

To demonstrate that postoperative pain secondary to Milligan and Morgan hemorrhoidectomy with Caiman® (AESCULAP®) and subsequent oral conventional analgesia is at least not greater than that generated after hemorrhoidectomy with monopolar diathermy and intravenous analgesia with care home at discharge.

Detailed description

In the treatment of coloproctological pathology, one of the most important problems is postoperative pain. Especially in the management of hemorrhoids treatment. There are different approaches but in all of them pain is the predominant symptom. There are some less painful techniques but the gold standard continues to be hemmorrhoidectomy, which is associated with postoperative pain. Some actions have been taken to control pain to avoid the admission of patients, but there are still problems in this regard. Our group aims to study the effect of energy change for performing hemorrhoidectomy on postoperative pain.

Interventions

PROCEDUREMonopolar Hemorroidecotmy

Hemorrhoidectomy with monopolar diathermy

PROCEDURECaiman Hemorroidectomy

Hemorrhoidectomy with Caiman® bipolar energy

Sponsors

Corporacion Parc Tauli
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Non-inferiority, prospective, randomized, single-center, parallel-group clinical trial.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* All patients with 2 or 3 bundles of grade III-IV hemorrhoids (Goligher classification) clinically symptomatic and subject to outpatient hemorrhoidectomy * Voluntary participation. * ASA I-II-III.

Exclusion criteria

* Failure to meet the inclusion criteria. * ASA IV. * Allergic to Paracetamol, derivatives of morphine. * Allergic to NSAIDs. * Synchronous colorectal neoplasia. * Coagulation disorders. * Thrombosed hemorrhoid. * Inflammatory bowel disease. * Liver cirrhosis and/or portal hypertension. * Pregnant women. * Difficulty following up by phone and/or in person.

Design outcomes

Primary

MeasureTime frameDescription
Visual analogue scale (VAS)6 hours of post-operative period (before hospital discharge performed); within 2 days with telephone control; at 7 days control at external consultations; at 30 days control at external consultationsPostoperative pain: value 0 (no pain) - 10 (maximum pain)

Secondary

MeasureTime frameDescription
Wexner scalein pre-operative visit, on the 7th and 30th postoperative clinical controlAssessment of fecal incontinence o a scale from 0 (never incontinence) to 4 (always), obtaining a score between 0 and 20.
Number of emergency consultationsin 30 days post-surgeryrevision of Database
Wound healing time7 days postoperative control at external consultations; 30 days postoperative control at external consultationsA healed wound is considered when all post-hemorrhoidectomy wounds of 2-3 bundles are epithelialized
Post-surgery satisfaction survey30 days postoperative control at external consultationsPhone checklist survey
Collection of adverse effects from patientsin 30 days post-surgeryrevision of Database

Countries

Spain

Contacts

Primary ContactLaura Mora
mora.lopez.laura@gmail.com34 937211010

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026